News
MS patients in rural areas are 17% less likely to receive DMTs than those in urban areas, a study of Alberta, Canada, ...
Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...
Aranzazu Calzado, known to friends as Zazu, has lived in Houston since 1996 after moving from Spain. Diagnosed with primary ...
Columnist Ben Hofmeister knows that living his best life is his mission, so he tries to put his multiple sclerosis in proper context.
Biostate AI and the Accelerated Cure Project will to develop AI models to predict multiple sclerosis progression and ...
Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to ...
The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...
MS patients in the U.S. with Medicaid coverage have worse disease outcomes compared with those who have private insurance, a ...
Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.
The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...
Sanam Saeedi, an MS health and life coach, was diagnosed with multiple sclerosis in 2017. She shares why self-advocacy is essential and how to push for the care you deserve. I would say, if your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results